Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

European Authorities Approve New Manufacturing Facility for Shire’s REPLAGAL® (agalsidase alfa)

June 24, 2011 By Bio-Medicine.Org

DUBLIN and LEXINGTON, Massachusetts, June 24, 2011 /PRNewswire/
—

 

Shire plc (LSE: SHP, NASDAQ:
SHPGY), the global specialty biopharmaceutical company, today
announced that the European Medicines Agency has approved the
purification of REPLAGAL® (agalsidase alfa) drug
substance at its new manufacturing facility in Lexington, MA, US.
 REPLAGAL, Shire’s enzyme replacement therapy for the
treatment of Fabry disease is the first product that will be made
available to patients from the new facility.

With this approval, the company now has two approved facilities
– Alewife, which is located in Cambridge, MA, as well as the new
Lexington facility – in which to purify REPLAGAL, thus providing
increased manufacturing flexibility. The cell culture portion of
the REPLAGAL manufacturing process will continue to be conducted at
Alewife.

 “We are pleased that we were able to accelerate the
construction and approval of our new manufacturing facility in
order to provide rapid access to important therapies for patients
in need,” said Bill Ciambrone, Senior Vice President of Technical
Operations, Shire HGT. “This new facility allows greater
flexibility to meet global demand for our products, including
REPLAGAL.”

Shire reiterated that it has sufficient product inventory to
continue to meet the needs of Fabry patients worldwide currently
receiving REPLAGAL and that it can meet anticipated additional
demand.  The Company is committed to continuing to provide
uninterrupted long-term access to the product at the licensed
dose.  

In addition to REPLAGAL, Shire anticipates regulatory agency
submission of the VPRIV (velaglucerase alfa) manufacturing process
at the new Lexington manufacturing facility by the end of 2011.

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leadin

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech